This market research study presents a detailed segmentation of the global autoimmune drugs market by type of disease (RA, MS, Psoriasis, IBD, AS, SLE), by mechanism of action (TNF inhibitors, IL blockers, COX inhibitors, and phosphodiesterase type 4 inhibitor), by drug class (DMARDs, NSAIDs, corticosteroids, analgesics, and immunosuppressant), and by geography (Americas, APAC, and EMEA). The top vendors identified in the market are AbbVie, Johnson & Johnson, Biogen, Amgen, and Pfizer.
Technavio’s market research analysts estimate the global autoimmune drugs market, to grow at a CAGR of 5% between 2016 and 2020. Increase in the prevalence of autoimmune diseases and the promising pipeline of drug candidates has boosted the sales of autoimmune drugs across the globe. The Americas account for around 52% of the total market share, thanks to the expanded access to medical care as a result of healthcare reforms.
The new market research report from Technavio provides a breakdown and analysis of the autoimmune drugs segments by technology.
“Of late, several nations are opting for biosimilars to provide quality care to patients without increasing their healthcare expenditure. Unlike generic drugs, biosimilars have identical active pharmaceutical ingredients to their originator biologic compounds. They are less expensive than biologics, thereby offer better patient access. The market is expected to witness increased sales of Remicade, Enbrel, and HUMIRA drugs in their biosimilar versions,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
The rheumatoid arthritis (RA) drugs segment lead the autoimmune drugs market, occupying more than 44% of the total market share. The two major segments of the RA drugs market are symptomatic drugs and DMARDs. In the symptomatic drugs segment, the TNF inhibitors hold the largest market share. This class of drugs offer long-term safety benefits leading to an augmented demand for these drugs. Moreover, the launch of TNF-alpha inhibitors biosimilars will aid in the growth of this market segment over the forecast period.
The key vendors in the global autoimmune drugs market are AbbVie, Johnson & Johnson, Biogen, Amgen, and Pfizer. The market is highly competitive due to the presence of many vendors offering multiple treatment options. Apart from the high cost of the drugs, the complex treatment of autoimmune diseases and a severe lack of effective diagnostic challenge the market. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
A more detailed analysis is available in the Technavio report, Global Autoimmune Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
